DHP2302R2

DHP2302R2 is a small molecule investigational drug developed by DAE HWA PHARM. It is currently being evaluated in Phase 1 clinical trials to assess its safety and pharmacokinetic drug-drug interactions, particularly when administered alone or in combination with another investigational agent, DHP2302R1. The primary study population has been healthy adult volunteers in South Korea. As of now, the specific mechanism of action, molecular target(s), therapeutic area(s), and active indications for DHP2302R2 have not been publicly disclosed[1][3][5]. The available data focus on early-phase safety and interaction studies rather than efficacy or disease-specific outcomes.

Other names

clopidogrel/rebamipide